ENV-ONC-101: Hedgehog Pathway Inhibitor in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsTaladegib
Condition: Solid Tumors
Sponsor: Endeavor Biomedicines, Inc.
ENV-ONC-101: A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Oral small molecule hedgehog pathway inhibitor taladegib
For patients with an advanced or metastatic solid tumor with a PTCH1 loss of function mutation that have been treated with and are refractory to all available standard of care therapy in their tumor type.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.